May 31, 2016
Cilag International NV has announced that the European Commission (EC) has approved the use of TREVICTA® (paliperidone palmitate a 3‑monthly injection) for treating schizophrenia in adult patients. TREVICTA will provide the longest dosing interval available in the European Union for an antipsychotic medication, which allows patients to maintain an optimal level of treatment in their blood with fewer administrations, compared to antipsychotic treatments available currently. This may improve outcomes for patients and healthcare professionals.
TREVICTA is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION®, a 1-monthly paliperidone palmitate product for the maintenance treatment of schizophrenia that was approved in 2011 by the European Union. The decision from the EC follows a Positive Opinion recommending the approval of TREVICTA from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in April 2016.
Dr Andreas Schreiner, European Therapeutic Area Leader, Neuroscience and Pain, Janssen, said: “This approval is a big step forward for people living with schizophrenia. With fewer administrations per year compared to other approved treatments, TREVICTA can give people with schizophrenia greater freedom to focus on other important aspects of their life and less on their treatment. This new option has the potential to reduce the likelihood of relapse and progression of the disease. It also helps healthcare professionals ensure the person with schizophrenia can benefit from continuous delivery of medication between administrations.”